OCTAPHARMA
14.2.2020 13:23:09 CET | Business Wire | Press release
Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019. We achieved good growth in all three of our therapeutic areas. We continued to invest significantly in R&D to fund the discovery and development of new life-changing treatments, as well as in our plasma collection capacities to ensure the future supplies of our life-saving products for patients. Our new subcutaneous immunoglobulin (SCIG), cutaquig®, received approval in Europe following approvals in 2018 in the USA and Canada. The European Medicines Agency (EMA) approved an updated label for our recombinant factor VIII (rFVIII), Nuwiq® to include data on effective bleed protection with twice weekly dosing using personalised prophylaxis. Fibryga® received European approval to treat acquired fibrinogen deficiencies, extending the earlier approval for use in patients with congenital fibrinogen deficiency. These approvals bring substantial benefits to patients as well as physicians. Based on our existing product portfolio and our development pipeline, Octapharma is well positioned to continue to perform strongly in the coming years .”
The Octapharma Group has delivered a strong performance in 2019. Sales of €2.2 billion represent an increase of €417 million (23.2%) compared to 2018. Furthermore, operating income increased by €78.6 million (22.7%) compared with 2018, to €424 million.
Gross profit in 2019 was €783 million, which is €152 million more than 2018. Despite continued investments in plasma collection and production capacities to fulfil the growing global demand for our products, gross margin increased by 0.3% to 35.4%.
Significant investments were made for the Group’s future prosperity in R&D and into the extension of plasma collection and production capacities. Important milestones in the expansion and utilisation of the plasma and recombinant product portfolio became a reality during the last 12 months. To ensure each litre of plasma is optimally used, the Group will continue to enter new markets and expand its portfolio with innovative new products and services.
“Last year our products touched hundreds of thousands of patients globally ,” said Roger Mächler, Chief Financial Officer of the Octapharma Group. “Our significant investments in research and infrastructure strongly position Octapharma to fulfil the unmet needs of more healthcare professionals and patients around the world in the coming years .”
The Annual Report 2019 provides a comprehensive overview of the Octapharma Group, including details of corporate governance and the financial results. To download the full Octapharma 2019 Annual Report visit: www.octapharma.com/annual-report .
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
At Octapharma, our passion drives us to provide new health solutions advancing human life. This is our vision. We thrive as an organisation in which people take ownership, have integrity, demonstrate grounded and confident leadership, drive sustainability, and are inspired by and eager to embrace entrepreneurship.
We employ more than 9,300 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care (bleeding management and functional volume replacement)
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, in addition to more than 120 plasma centres across Europe and the US. For more information visit: www.octapharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200214005230/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
